Breaking News Instant updates and real-time market news.

ACHN

Achillion

$4.01

0.04 (1.01%)

16:26
08/08/17
08/08
16:26
08/08/17
16:26

Achillion reports Q2 EPS (16c), consensus (16c)

Achillion's cash, cash equivalents, marketable securities, and interest receivable as of June 30 were $369.9M.

  • 08

    Aug

ACHN Achillion
$4.01

0.04 (1.01%)

04/24/17
BARD
04/24/17
NO CHANGE
Target $5
BARD
Outperform
Achillion price target lowered to $5 from $10 at Baird
Baird analyst Brian Skorney lowered his price target on Achillion (ACHN) to $5 from $10 on its disappointing Hep-C results, which indicated a weakness when it comes to genotype 3 patients. Although he expects partner Johnson & Johnson (JNJ) to push the trial into Phase 3, he think it makes the regimen a more difficult sell with other drugs offering genotype 3 efficacy. Skorney maintained his Outperform rating on Achillion shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/25/17
MAXM
04/25/17
NO CHANGE
Target $5
MAXM
Buy
Achillion price target lowered to $5 from $8 at Maxim
Maxim analyst Jason Kolbert said phase 2 trial results demonstrated that Achillion's (ACHN) triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration, be generally well tolerated and offer high efficacy for hepatitis C virus genotype 1 patients. While Johnson & Johnson (JNJ) is likely to move forward with this regimen, allowing Achillion to realize milestones, Kolbert has removed any royalties from his model as he expects others to dominate the landscape with "near perfect" regimens. Kolbert lowered his price target on Achillion to $5 from $8 but keeps a Buy rating on the shares.
05/18/17
LEER
05/18/17
UPGRADE
Target $6
LEER
Outperform
Achillion upgraded to Outperform from Market Perform at Leerink
Leerink analyst Joseph Schwartz upgraded Achillion Pharmaceuticals (ACHN) and raised his price target for the shares to $6 from $4. The analyst sees limited downside from current share levels even if the complement study fails, assuming the hepatitis C virus partnership with Johnson & Johnson (JNJ) remains intact. Schwartz assigned a "conservative" 33% probability of success to Achillion's complement program due to the lack of precedent for an oral small molecule inhibitor of complement factor D that is selective enough to avoid off target effects. He believes risks to successful ACH-4471 development are fully discounted in Achillion's current stock price.

TODAY'S FREE FLY STORIES

PDD

Pinduoduo

$20.26

-0.34 (-1.65%)

12:25
12/10/18
12/10
12:25
12/10/18
12:25
Options
Pinduoduo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
12/10/18
12/10
12:25
12/10/18
12:25
General news
Euro$ interest rate futures perked up »

Euro$ interest rate…

BCO

Brink's

$61.25

-0.85 (-1.37%)

12:22
12/10/18
12/10
12:22
12/10/18
12:22
Conference/Events
Brink's management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

QCOM

Qualcomm

$57.75

1.75 (3.13%)

, AAPL

Apple

$164.67

-3.7 (-2.20%)

12:20
12/10/18
12/10
12:20
12/10/18
12:20
Recommendations
Qualcomm, Apple analyst commentary  »

Injunction may be first…

QCOM

Qualcomm

$57.75

1.75 (3.13%)

AAPL

Apple

$164.67

-3.7 (-2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTRI

Nutrisystem

$44.15

9.96 (29.13%)

12:17
12/10/18
12/10
12:17
12/10/18
12:17
Downgrade
Nutrisystem rating change  »

Nutrisystem downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/10/18
12/10
12:17
12/10/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLD

TopBuild

$46.22

-0.96 (-2.03%)

12:16
12/10/18
12/10
12:16
12/10/18
12:16
Conference/Events
TopBuild management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/10/18
12/10
12:16
12/10/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$49.62

-2.44 (-4.69%)

12:15
12/10/18
12/10
12:15
12/10/18
12:15
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CCK

Crown Holdings

$47.82

-0.22 (-0.46%)

12:14
12/10/18
12/10
12:14
12/10/18
12:14
Conference/Events
Crown Holdings to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRDXF

Nordex

$0.00

(0.00%)

12:13
12/10/18
12/10
12:13
12/10/18
12:13
Upgrade
Nordex rating change  »

Nordex upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:10
12/10/18
12/10
12:10
12/10/18
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

KO

Coca-Cola

$48.84

-0.24 (-0.49%)

12:08
12/10/18
12/10
12:08
12/10/18
12:08
Periodicals
Coca-Cola hires broker to sell iconic Fifth Avenue building, Bloomberg says »

Coca-Cola has enlisted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 18

    Dec

  • 03

    Mar

DLAKY

Lufthansa

$0.00

(0.00%)

, EADSY

Airbus

$0.00

(0.00%)

12:07
12/10/18
12/10
12:07
12/10/18
12:07
Periodicals
Avianca CEO wants to cut Airbus order by as much as half, Reuters says »

Avianca Holdings (AVH)…

DLAKY

Lufthansa

$0.00

(0.00%)

EADSY

Airbus

$0.00

(0.00%)

AVH

Avianca

$4.91

-0.39 (-7.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$165.25

-3.12 (-1.85%)

, QCOM

Qualcomm

$58.05

2.05 (3.66%)

12:06
12/10/18
12/10
12:06
12/10/18
12:06
OnTheFly
Fly Intel: Wall Street's top stories at midday »

The averages were…

AAPL

Apple

$165.25

-3.12 (-1.85%)

QCOM

Qualcomm

$58.05

2.05 (3.66%)

FB

Facebook

$140.74

3.32 (2.42%)

GPRO

GoPro

$4.94

-0.04 (-0.80%)

TVPT

Travelport

$15.68

0.275 (1.79%)

NTRI

Nutrisystem

$44.14

9.95 (29.10%)

TVTY

Tivity Health

$28.53

-12.07 (-29.73%)

XPER

Xperi

$18.34

5.54 (43.28%)

SSNLF

Samsung

$0.00

(0.00%)

MDRX

Allscripts

$10.15

0.66 (6.95%)

MGNX

MacroGenics

$12.00

-4.44 (-27.01%)

CRZO

Carrizo Oil & Gas

$14.69

-1.2 (-7.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 06

    Jan

KZR

Kezar Life Sciences

$27.79

0.41 (1.50%)

12:05
12/10/18
12/10
12:05
12/10/18
12:05
Conference/Events
Kezar Life Sciences management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

T

AT&T

$29.50

-0.64 (-2.12%)

12:05
12/10/18
12/10
12:05
12/10/18
12:05
Options
AT&T call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 20

    Mar

BC

Brunswick

$49.53

-0.05 (-0.10%)

12:02
12/10/18
12/10
12:02
12/10/18
12:02
Conference/Events
Brunswick management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

AJG

Arthur J. Gallagher

$73.87

-0.74 (-0.99%)

12:01
12/10/18
12/10
12:01
12/10/18
12:01
Hot Stocks
Arthur J. Gallagher acquires Captive Insurance Company Design and Operations »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

JP

Jupai Holdings

$5.06

-0.94 (-15.67%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Jupai Holdings falls -15.8% »

Jupai Holdings is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSC

Global Geoscience

$23.90

(0.00%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Global Geoscience falls -16.2% »

Global Geoscience is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPX

Marine Products

$18.19

-3.4 (-15.75%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Marine Products falls -18.3% »

Marine Products is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPER

Xperi

$18.39

5.59 (43.67%)

, SSNLF

Samsung

$0.00

(0.00%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Recommendations
Xperi, Samsung analyst commentary  »

Xperi settlement removes…

XPER

Xperi

$18.39

5.59 (43.67%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

FAZ

Direxion Financial Bear 3x

$12.50

0.67 (5.66%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Direxion Financial Bear 3x rises 5.8% »

Direxion Financial Bear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCUS

Arcus Biosciences

$13.15

0.9 (7.35%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Arcus Biosciences rises 8.1% »

Arcus Biosciences is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.